Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement

Rheumatology International

Volumn 32, Issue 11, 2012, Pages 3373-3382

  Morton, Muir ^a   Edmonds, Sarah ^a   Doherty, Aislinn M ^a   Dhaygude, Ajay ^b   Helbert, Matthew ^c   Venning, Mike ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Granulomatosis with polyangiitis; Immunosuppression; Infection; Lymphopenia; Systemic lupus erythematosis

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL FACTOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GRANULOMATOSIS; HEMORRHAGIC CYSTITIS; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; POLYARTERITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS; WEGENER GRANULOMATOSIS;

EID: 84872184220     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2151-0     Document Type: Article

References (42)

1. Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthr Rheum 38:551-558
2. Patel M, Clarke AM, Bruce IN, Symmons DP (2006) The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthr Rheum 54:2963-2969 (Pubitemid 44497777)
3. Dhaygude A, Bruce IN, O'Donoghue D et al (2007) Incidence of biopsy proven pauci-immune necrotising/crescentic glomerulonephritis in Greater Manchester. J Am Soc Nephrol 18:FP0995
4. Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthr Rheum 43:414-419 (Pubitemid 30395752)
5. Falk RJ, Gross WL, Guillevin L et al (2011) Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 70:704
6. Bolton WK, Sturgill BC (1989) Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9:368-375 (Pubitemid 19245923)
7. Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthr Rheum 58:2908-2918
8. Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180-2188 (Pubitemid 47041083)
9. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthr Res Ther 11:R109
10. Gescuk BD, Davis JC Jr. (2002) Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 14:515-521 (Pubitemid 34959978)
11. Illei GG, Austin HA, Crane M et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248-257 (Pubitemid 32799338)
12. Jayne D (2000) Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 39:585-595
13. Austin HA III, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619 (Pubitemid 16132725)
14. Cohen J, Pinching AJ, Rees AJ, Peters DK (1982) Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. QJ Med 51:1-15 (Pubitemid 13160887)
15. Houssiau FA, Vasconcelos C, D'Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthr Rheum 46:2121-2131
16. Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthr Rheum 40:2187-2198 (Pubitemid 28016415)
17. Charlier C, Henegar C, Launay O et al (2009) Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 68:658-663
18. Jallouli M, Frigui M, Marzouk S, Maaloul I, Kaddour N, Bahloul Z (2008) Infectious complications in systemic lupus erythematosus: a series of 146 patients. Rev Med Interne 29:626-631
19. Pagnoux C, Cohen P, Hamidou M et al (2005) Treatment of ANCA-Associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT). American College of Rheumatology, 69th annual scientific meeting, San Diego. Arthr Rheum 52
20. de Groot K, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized trial. Ann Intern Med 150:670-680
21. Sinclair A, Appel G, Dooley MA et al (2007) Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16:972-980
22. Bradley JD, Brandt KD, Katz BP (1989) Infectious complications of cyclophosphamide treatment for vasculitis. Arthr Rheum 32: 45-53 (Pubitemid 19034923)
23. Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-Associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776-784 (Pubitemid 36396745)
24. Jarrousse B, Guillevin L, Bindi P et al (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 11:615-621 (Pubitemid 24000159)
25. Krafcik SS, Covin RB, Lynch JP III, Sitrin RG (1996) Wegener's granulomatosis in the elderly. Chest 109:430-437 (Pubitemid 26058601)
26. Falagas ME, Manta KG, Betsi GI, Pappas G (2007) Infectionrelated morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26:663-670 (Pubitemid 46554069)
27. Morgan BP, Walport MJ (1991) Complement deficiency and disease. Immunol Today 12:301-306
28. Foster CB, Lehrnbecher T, Mol F et al (1998) Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 102: 2146-2155 (Pubitemid 29018821)
29. Keeling DM, Isenberg DA (1993) Haematological manifestations of systemic lupus erythematosus. Blood Rev 7:199-207 (Pubitemid 24004827)
30. Nived O, Sturfelt G, Wollheim F (1985) Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 55:271-287 (Pubitemid 15028242)
31. Nossent JC, Swaak AJ (1991) Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 80:605-612
32. Higgins RM, Goldsmith DJ, Connolly J et al (1996) Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad Med J 72:41-44 (Pubitemid 26018008)
33. Hunder GG, Arend WP, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthr Rheum 33:1065-1067 (Pubitemid 20273289)
34. Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr Rheum 37:187-192 (Pubitemid 24065492)
35. Lapraik C, Watts R, Bacon P et al (2007) BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46:1615-1616
36. Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036-1043
37. Gibson KL, Gipson DS, Massengill SA et al (2009) Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 4:1962-1967
38. Dhaygude A, Griffith M, Cairns T, McLean A, Palmer A, Taube D (2004) Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-Associated vasculitis. Nephron Clin Pract 97:c154-c159 (Pubitemid 39179249)
39. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD (1995) Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 25:380-389
40. Pilheu JA, De Salvo MC, Gonzalez J, Rey D, Elias MC, Ruppi MC (1997) CD4? T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. Int J Tuberc Lung Dis 1:422-426 (Pubitemid 127509625)
41. Goupil R, Nadeau-Fredette A, Troyanov S, Brachemi S (2010) Severe lymphopenia is frequent and predictive of infectious complications in ANCA vasculitis. American Society of Nephrology Renal Week, Denver
42. Stanford E, Print F, Falconer M et al (2009) Immune response to pneumococcal conjugate vaccination in asplenic individuals. Hum Vaccin 5:85-91